Dec 20, 2024 · Once-weekly subcutaneous CagriSema is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme).

5 days ago · Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125...

4 days ago · Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential successor to Wegovy (semaglutide), as the company aims to quell uncertainty over the therapy’s efficacy ceiling.. The Danish drugmaker plans to conduct the trial, called REDEFINE 11, with a longer duration and focus on dose escalation and reescalation.

Jan 2, 2025 · When evaluating under the trial product estimand, findings showed CagriSema-treated patients achieved a superior weight loss of 22.7% compared with 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo after 68 weeks.

Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...

6 days ago · Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in ...

REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual...

Jul 17, 2023 · Clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising new type 2 diabetes and weight management treatment. Developed by Novo Nordisk, CagriSema is a combination medication of cagrilintide and the GLP-1 receptor agonist semaglutide.

Nov 15, 2023 · Novo has unveiled a new phase 3 trial pitting CagriSema, a fixed-dose combination of Wegovy and the investigational drug cagrilintide, against Lilly’s Zepbound in people with obesity, according...

3 days ago · Individualized treatment could boost weight loss with Novo Nordisk’s up-and-coming treatment CagriSema, which disappointed investors late last year after failing to meet the company’s own bar of 25% weight reduction. Novo has recently released two readouts from its closely watched weight loss pipeline.